Literature DB >> 30919550

Natriuretic peptides as a surrogate endpoint in clinical trials - a riddle wrapped in an enigma.

Alexander B Hardwick1, Andrew P Ambrosy1,2.   

Abstract

Year:  2019        PMID： 30919550     DOI： 10.1002/ejhf.1448

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


× No keyword cloud information.
  2 in total

1.  Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.

Authors:  Atsushi Tanaka; Shigeru Toyoda; Takumi Imai; Kazuki Shiina; Hirofumi Tomiyama; Yasushi Matsuzawa; Takahiro Okumura; Yumiko Kanzaki; Katsuya Onishi; Arihiro Kiyosue; Masami Nishino; Yasushi Sakata; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2021-09-03       Impact factor: 9.951

2.  Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.

Authors:  Kenya Kusunose; Takumi Imai; Atsushi Tanaka; Kaoru Dohi; Kazuki Shiina; Takahisa Yamada; Keisuke Kida; Kazuo Eguchi; Hiroki Teragawa; Yasuchika Takeishi; Nobuyuki Ohte; Hirotsugu Yamada; Masataka Sata; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2021-09-14       Impact factor: 9.951
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.